FREGAT Trial (2019): Minimally Invasive Esophagectomy for Esophageal Cancer


Source: NEJM

FREGAT Trial Key Points

  1. Minimally invasive esophagectomy (MIE) was found to have significantly lower complications and side effects compared to open esophagectomy.
  2. The 3 years survival rate was also higher among patients undergoing minimal invasive esophagectomy.
  3. Open esophagectomy is known to have significant morbidity ranging from 17.9% to 58%, with up to 6% mortality. Therefore, the minimally invasive hybrid procedure is now being utilized to limit the adverse events.